Recombinant live influenza vaccine virus—tests of transmissibility in man

Beare, A. S.; Habershon, R. B.; Tyrrell, D. A. J.; Hall, T. S.

doi:10.1016/0092-1157(73)90017-6

Cited by 9 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Any live influenza vaccine therefore must be shown to be stable and non-reactogenic, and must give rise to little or no transmission. Evidence of transmission to close contacts from virus shedding has been observed previously with live influenza vaccines (McDonald, Zuckerman, Beare & Tyrrell, 1962), but has not been found within a closed population (Davenport et al 1971;Beare, Habershon, Tyrrell & Hall, 1973;Lamy et al 1973).…”

Section: Introductionmentioning

confidence: 89%

Comparative trials of live attenuated and detergent split influenza virus vaccines

Mackenzie¹,

MacKenzie²,

Lloyd³

et al. 1975

J. Hyg.

View full text Add to dashboard Cite

SUMMARYComparative clinical trials of live attenuated and detergent-split subunit influenza virus vaccines were undertaken with 1048 volunteers in Western Australia. Volunteers were divided into three main groups, each of which received either live virus vaccine or a saline control administered intranasally, or subunit vaccine injected subcutaneously. No differences were recorded between the three groups in their post-vaccination symptoms. Serum samples were collected at various times up to 50 weeks after vaccination, and antibody titres were measured by haemagglutination-inhibition (HI) tests and, for 231 volunteers, by virus neutralization tests. The two vaccines were almost equivalent in inducing seroconversion in vaccinees with pre-trial HI titres of 96 or less, but the subunit vaccine stimulated a higher geometric mean HI antibody titre. The longevity of the HI antibody response was greater for the live virus vaccine. The height of the response and the longevity of neutralizing antibody were the same for both vaccines. Both vaccines provided a high degree of protection against epidemic A/England/42/72 influenza, and some protection against A/Port Chalmers/1/73 influenza.

show abstract

Section: Introductionmentioning

confidence: 89%

Comparative trials of live attenuated and detergent split influenza virus vaccines

Mackenzie¹,

MacKenzie²,

Lloyd³

et al. 1975

J. Hyg.

View full text Add to dashboard Cite

show abstract

“…A high degree of stability of attenuation and a virtually absent transmissibility to susceptible contacts has been reported for these vaccines (Murphy et al 1972;Beare et al 1973;Iki6 et al 1977). Immunization produces a high incidence of * This work was supported by contract No.…”

Section: Introductionmentioning

confidence: 93%

Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease

Rocchi¹,

Ragona²,

Piga³

et al. 1979

J. Hyg.

View full text Add to dashboard Cite

Immunization procedures with live attenuated and inactivated vaccines were carried out on a group of young recruits at the beginning of an outbreak of infection due to an A/Victoria/3/75-related virus strain, which occurred in February 1977 in a military camp. A retrospective investigation on protection from clinical influenza was then performed in order to investigate whether immunization with live virus vaccines, administered at the beginning of an epidemic, could provide early protection from the disease. In the course of the two weeks following vaccination, laboratory-confirmed clinical influenza cases occurred in 4 subjects among the 110 volunteers of the control group which received placebo, and in 8, 7 and 4 subjects respectively of the 3 groups of about 125 individuals, each of which received one of the following vaccine preparations: (a), live attenuated A/Victoria/3/75 influenza virus oral vaccine, grown on chick embryo kidney culture; (b), live attenuated nasal vaccine, a recombinant of A/Puerto Rico/8/34 with A/Victoria/3/75 virus; and (c), inactivated A/Victoria/3/75 virus intramuscular vaccine. These data do not support the hypothesis that, during an epidemic of infection, early protection from clinical influenza can be achieved through immunization with live attenuated or inactivated influenza virus vaccines, in spite of the high immunizing capability of the vaccine preparations.

show abstract

“…McDonald et al (32) reported transmission to close contacts in a clinical trial in the Royal Air Force, and we have found serological evidence of transmission between husbands, who had received live vaccine, and their wives, although this was relatively rare. No evidence of transmission has been observed in clinical trials in such closed communities as a state mental institution (9) and a monastery (3).…”

Section: Transplacental Transmissionmentioning

confidence: 99%

Influenza infections during pregnancy: association with congenital malformations and with subsequent neoplasms in children, and potential hazards of live virus vaccines.

Mackenzie¹,

Houghton²

1974

Bacteriological Reviews

View full text Add to dashboard Cite

INTRODUCTION 356 ASSOCIATION OF INFLUENZA INFECTIONS DURING PREGNANCY AND CONGENITAL MALFORMATIONS 356 Problems in Interpretation .356 Evidence for and Against an Association .357 CNS malformations .357 Circulatory malformations .360 Cleft lip and reduction deformities .361 Other reports suggesting an association between influenza and congenital malformations .361 Reports unable to substantiate an association between influenza and congenital malformations .362 Evidence from Animal Models .

show abstract

Recombinant live influenza vaccine virus—tests of transmissibility in man

Cited by 9 publications

References 5 publications

Comparative trials of live attenuated and detergent split influenza virus vaccines

Comparative trials of live attenuated and detergent split influenza virus vaccines

Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease

Influenza infections during pregnancy: association with congenital malformations and with subsequent neoplasms in children, and potential hazards of live virus vaccines.

Contact Info

Product

Resources

About